DOI=10.4172/2161-0681.1000119
Robertson F.M., Chu K., Fernandez S.V., Mu Z.-M., Zhang X.-J., Liu H., Boley K.M., Alpaugh R.K., Ye Z.-M., Wright M.C., Luo A.Z., Oraes R., Wu H., Zook M.B., Barsky S.H., Krishnamurthy S., Cristofanilli M.
Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFbeta signaling.
J. Clin. Exp. Pathol. 2:119.1-119.11(2012)

PubMed=23784380; DOI=10.1007/s10549-013-2600-4; PMCID=PMC4273486
Fernandez S.V., Robertson F.M., Pei J.-M., Aburto-Chumpitaz L.D., Mu Z.-M., Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z.-M., Cai K.Q., Boley K.M., Klein-Szanto A.J.P., Devarajan K., Addya S., Cristofanilli M.
Inflammatory breast cancer (IBC): clues for targeted therapies.
Breast Cancer Res. Treat. 140:23-33(2013)

PubMed=35042871; DOI=10.1038/s41523-021-00379-6; PMCID=PMC8766434
Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
NPJ Breast Cancer 8:12.1-12.12(2022)